{{Chembox
| ImageFile = Diquafosol.svg
| ImageSize = 250px
| IUPACName = <nowiki>[[[[</nowiki>(2''R'',3''S'',4''R'',5''R'')-5-(2,4-Dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl] [(2''R'',3''S'',4''R'',5''R'')-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate
| OtherNames = P1,P4-Bis(5'-uridyl) tetraphosphate; INS-365; Diquafosol tetrasodium 
|Section1={{Chembox Identifiers
| IUPHAR_ligand = 1736
| CASNo = 59985-21-6
| CASNo_Ref = {{cascite|correct|}}
| CASNo1 = 211427-08-6
| CASNo1_Ref = {{cascite|correct|}}
| CASNo1_Comment = (tetrasodium salt)
| UNII = 7828VC80FJ
| PubChem = 148197 
| PubChem1 = 148196
| PubChem1_Comment = (tetrasodium salt)
| ChemSpiderID = 130647
| ChemSpiderID1 = 130646
| ChEMBL = 1767408
| ChEMBL2 = 221326
| ChemSpiderID1_Comment = (tetrasodium salt)
| SMILES = O=C1\C=C/N(C(=O)N1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]4O[C@@H](N\3C(=O)NC(=O)/C=C/3)[C@H](O)[C@@H]4O
| InChI = 1/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1
| InChIKey = NMLMACJWHPHKGR-NCOIDOBVBD
| StdInChI = 1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1
| StdInChIKey = NMLMACJWHPHKGR-NCOIDOBVSA-N
  }}
|Section2={{Chembox Properties
| C=18 | H=26 | N=4 | O=23 | P=4 
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility =
  }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
  }}
|Section5={{Chembox Pharmacology
| AdminRoutes =
| Bioavail =
| Excretion =
| HalfLife =
| Metabolism =
| Legal_status =
| Legal_US =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| PregCat =
| PregCat_AU =
| PregCat_US =
| ProteinBound = }}
}}

'''Diquafosol''' (tradename '''Diquas''') is a pharmaceutical drug for the treatment of [[dry eye disease]]. It was approved for use in Japan in 2010.<ref>{{cite web| url = http://www.businesswire.com/news/home/20100416005914/en/Santen-Inspire-Announce-Approval-DIQUASTM-Dry-Eye | title = Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan | date = April 16, 2010}}</ref> It is formulated as a 3% ophthalmic solution of the [[sodium|tetrasodium]] [[salt (chemistry)|salt]].

Its [[mechanism of action]] involves [[agonist|agonism]] of the [[P2RY2|P2Y2 purinogenic receptor]].<ref>{{cite journal | pmid = 11206448 | year = 2001 | last1 = Pendergast | first1 = W | last2 = Yerxa | first2 = BR | last3 = Douglass Jg | first3 = 3rd | last4 = Shaver | first4 = SR | last5 = Dougherty | first5 = RW | last6 = Redick | first6 = CC | last7 = Sims | first7 = IF | last8 = Rideout | first8 = JL | title = Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates | volume = 11 | issue = 2 | pages = 157â€“60 | journal = Bioorganic & Medicinal Chemistry Letters | doi=10.1016/S0960-894X(00)00612-0}}</ref>

==References==
{{reflist}}

{{Purinergics}}

[[Category:Ophthalmology drugs]]
[[Category:Nucleotides]]